The aim of this study was to investigate the effect of quercetin on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome (PCOS). In this randomized, double-blind, placebo-controlled trial, 78 overweight or obese women 
| INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women at reproductive age, which is mainly characterized by hyperandrogenemia, polycystic ovaries, ovulatory dysfunction, and infertility (Norman, Dewailly, Legro, & Hickey, 2007) . In addition, it has been recognized that insulin resistance, hyperinsulinemia, and dyslipidemia are the common metabolic features of PCOS, which could contribute to type 2 diabetes and metabolic syndrome (Carreau & Baillargeon, 2015) . Insulin resistance is one of the main reasons of increased blood androgen levels, and in turn, androgens may contribute to insulin resistance by elevating free fatty acids and changing muscle composition and function (Rojas et al., 2014) . Obesity has not been considered as a certain cause of PCOS, but it could exacerbate PCOS associated metabolic complications and affect the efficacy of treatments (Legro, 2012) .
One of the recent proposed mechanisms for insulin resistance is adipose tissue dysfunction and the imbalance of adipose secreted factors, known as adipokines or adipocytokines. Resistin, the adipoctytokine that is mainly produced by macrophages of the adipose tissue, has been well described to be involved in induction of inflammatory pathways and metabolic disorders including insulin resistance (Bokarewa, Nagaev, Dahlberg, Smith, & Tarkowski, 2005) .
Studies have shown that treatment with antidiabetic drugs could suppress resistin expression and increase insulin sensitivity (Steppan et al., 2001) .
Resistin blood concentration increases in people with insulin resistance and type 2 diabetes (Tokuyama et al., 2007) . It has also been shown that plasma levels of resistin are higher in patients with PCOS than healthy people, which could suggest the contributory role of resistin in insulin resistance and hyperinsulinemia (Mahde, Shaker, & Al-Mashhadani, 2009) . A clinical study showed the efficacy of rosiglitazone in alleviating plasma resistin in patients with PCOS (Majuri et al., 2007) . Some experimental studies have shown that antioxidants like folic acid (Seto et al., 2010) and quercetin (Zhang, et al., 2013a) might have similar effects in reducing resistin. However, currently no clinical trial is available to study the effect of dietary compounds on this peptide in PCOS.
Quercetin is a flavonol (a class of flavonoids) type antioxidant that exists naturally in many foods such as apples, tea, onions, mustard, grapes, and berries. Quercetin has been proposed to affect glucose homeostasis and inflammatory cascades. Previous studies in diabetic rats showed that quercetin supplementation reduces TNF-α, blood pressure, body mass index (BMI), hyperinsulinemia, insulin resistance, and dyslipidemia (Rivera, Morón, Sánchez, Zarzuelo, & Galisteo, 2008) . Besides, administration of quercetin in rats with PCOS significantly reduced levels of insulin, androgens, and lipid profile (Shah & Patel, 2016) .
We hypothesized that quercetin probably mediates the favorable effects, at least in part, by reducing the expression and plasma concentration of resistin. Therefore, this study was conducted to investigate the effect of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with PCOS. approved by ultrasonography, when at least two of the three described items were confirmed. In this study, postmenopausal women, participants with diabetes, thyroid and other endocrine disorders, and those who take insulin, insulin sensitizers, and other glucose lowering medications, contraceptives, weight loss agents, and antiinflammatory drugs were not included. The sample size of n = 40 in each group was calculated considering a power of 90% to detect five-unit change in resistin concentration between the two groups, with an assumed standard deviation (SD) of 6.65 in each group (Yilmaz et al., 2009 ), a type 1 error of 0.05, and a dropout rate of 5%. 
| Study design
All patients were randomly assigned to two groups, based on permuted block randomization to receive a total daily dose of either 1,000-mg quercetin (Jarrow, USA) or placebo. Supplement and placebo were provided in 500-mg capsules, and patients were instructed to consume two capsules per day with main meals (preferentially breakfast and lunch) for 12 weeks. It has been shown that oral administration of quercetin in doses of 4 g/day has no side effects in human (Lamson & Brignall, 2000) . Placebo and quercetin capsules were identical in shape and size and were coded as A and B by a blind statistician. Patients and the research team were blinded to treatment allocation.
Participants were advised not to change their dietary intake and level of physical activity during the study period. Dietary intake was assessed through 24-hr food recall (two weekdays and one weekend) by an expert person. Nutritionist IV software (First Databank, SanBruno, CA, USA) was used to calculate energy, macronutrients, and micronutrients intake at baseline and the end of the study.
In this trial, changes in plasma concentration and gene expression of resistin were considered as primary outcomes, while insulin resistance and levels of sex hormones were considered as secondary outcomes.
| Assessments
The body weight was measured in light clothing using a digital scale (Seca, Germany) with an accuracy of 100 g. The patients' height without shoes was measured by a wall-mount measuring tape (Seca, Germany). BMI was calculated as weight in kilograms divided by the square of height in meters. All anthropometric measurements were performed by a single observer before and after 12-week supplementation.
At baseline and at the end of 12-week intervention, 15 ml fasting (10-12 hr) venous blood sample was taken between 7 and 9 a.m. at one of the hospitals affiliated to Tehran University of Medical Sciences. For isolation of peripheral blood mononuclear cells (PBMC), 10 ml of blood samples were transferred to a heparinized falcon tube (20 U/ml). For serum separation, 5 ml of blood sample was taken and centrifuged at 3,500 rpm for 10 min. The serum was transferred to sterile microtubes and kept in −80°C until the tests were performed. were performed on the Step One7500 RT-PCR System (Applied Biosystems, USA). RT-PCR was carried out using SYBR Green Kit (TaKaRa, Japan) with gene-specific primers. Beta actin was used as the housekeeping gene; and the sequence of primers is shown in Table 1 . Changes of resistin mRNA expression were determined for each participant using the 2 − (ΔΔCt) method.
| Statistical analysis
All statistical analyses were performed using SPSS version 19 (SPSS Inc., Chicago, IL, USA). The normal distribution of quantitative data was confirmed by Kolmogorov-Smirnov test and Q-Q plot. Results have been presented as mean ± SD. Independent t test and paired t test were used to compare mean values between the two groups and within groups before and after the intervention, respectively.
Analysis of covariance was used to determine the effect of confounding variables including BMI changes, age, baseline waist circumference (WC), and baseline differences between two groups, on outcomes. Differences were considered as significant if p value < 0.05.
| RESULTS
Seventy-eight patients successfully completed the study (n = 39 in the quercetin and n = 39 in the placebo, group). One patient in each group was reluctant to continue the study. No side effect was observed during supplementation with quercetin ( Figure 1 ). The mean age of the patients in quercetin and placebo groups were 29.5 ± 4.2 versus 30 ± 5.5 years, respectively (p = 0.662). Baseline characteristics of the study population including anthropometries are presented in Table 2 .
Among anthropometric indexes, WC was significantly higher in the quercetin group at baseline (p = 0.034). After 12-week supplementation, weight (p < 0.001) and BMI (p < 0.001) decreased significantly in the quercetin group. There was no considerable difference in anthropometric variables at the end of the study between two groups. There was no significant difference in reported dietary energy intake at baseline or at the end of the study (Table 2) .
A significant decrease has been observed in plasma concentration of resistin (−0.81 ± 0.45 versus 0.02 ± 0.49 ng/ml, p < 0.001) in quercetin compared with the placebo group following supplementation, which remained statistically significant after adjustment for age, baseline WC, BMI changes, and baseline levels of this variable (Table 3 ). In addition, resistin gene expression decreased 36% (0.64 ± 0.58 vs.
1 ± 0.56, p = 0.008) in quercetin compared with the placebo group based on 2 -(ΔΔCt) calculation ( Figure 2 ).
As shown in Table 3 and LH (8.05 ± 2.88 vs. 8.77 ± 1.99 mIU/ml, P = 0.035) were observed in the quercetin compared with the placebo group at the end of the study. There was no significant difference in SHBG levels between the two groups following supplementation (p = 0.261; Table 3 ).
| DISCUSSION
In this 12-week study, we demonstrated that daily consumption of 1,000-mg quercetin supplementation in overweight or obese women and glucose metabolism independent of body weight status (Moscavitch et al., 2016) . It has been suggested that resistin might play a critical role in the pathogenesis of the disease due to about twofold overexpression in adipocytes of patients with PCOS (Seow et al., 2004) . In this study, it has been demonstrated that 1,000 mg daily quercetin can downregulate the resistin gene expression and subsequently decrease its plasma levels in PCOS. Alanbay et al. have reported low-grade chronic inflammation in normal weight and overweight women with PCOS based on a chronic activated macrophage marker, chitotriosidase activity (Alanbay et al., 2012) . Furthermore, previous studies have indicated that inflammation has a direct correlation with insulin resistance and could be considered as a part of treatment in patients with PCOS (Jian-huai & Zuan-sun, 2005) . It has been recognized that quercetin has anti-inflammatory properties, which could be done by inhibition of cyclooxygenase and lipoxygenase enzymes activity and thus production of prostaglandin E2, thromboxane A2, and leukotriene B4, and also inhibition of the proinflammatory adipocytokine TNF-α (Rivera et al., 2008) . The administration of quercetin in doses of 75 mg/kg/day and 300 mg/ kg/day for 8 weeks in rats with nonalcoholic fatty liver disease significantly reduced serum levels of resistin, IL-18, FBG, fasting insulin, and HOMA-IR compared with the untreated group (Zhang, et al., 2013b ).
In addition, Egert et al. (2009) found that quercetin supplementation for 6 weeks (150 mg/day) could significantly decrease serum levels of TNF-α compared to baseline in overweight participants (Egert et al., 2009) nonalcoholic fatty liver disease (Wang et al., 2016) . Furthermore, quercetin could significantly inhibit C/EBPα gene expression in preadipocytes (Yang, Li, Gao, Zhang, & Cai, 2012) . We did not assess these mechanisms directly in our study. However, based on these data, probably the reduction in plasma and gene expression of resistin following quercetin supplementation might be due to the modulation of inflammatory pathways and decrease in expression of adipogenic transcription factors. This hypothesis needs to be approved by further investigations.
It could be speculated that changes in the concentration and expression of resistin might be secondary to changes in body weight and fat mass. Some experimental evidence also proposed the potential weight loss effect of quercetin. It has been demonstrated that quercetin reduces adipogenesis and differentiation of preadipocytes through downregulation of peroxisome proliferatoractivated receptor gamma, C/EBPα, and AMP-activated protein kinase, as principal transcriptional regulators of these pathways, and also the inhibition of the obesity associated factor c-Jun Nterminal kinase (JNK) (Ahn, Lee, Kim, Park, & Ha, 2008) . Some animal studies reported the effect of short term quercetin supplementation on body weight and fat reduction in obese Zucker rats (10 mg/KgBW for 10 weeks) (Rivera et al., 2008) and streptozotocin-induced diabetes C57/BL6J mice (0.1% and 0.5% of the diet for 2 weeks) (Kobori, Masumoto, Akimoto, & Takahashi, 2009 ). On the other hand, quercetin supplementation (500 mg/day) for 8 weeks was not associated with weight loss in athletic men (Askari et al., 2013) . Our findings could not also show any beneficial effect on anthropometric indexes. Although we observed statistically significant reduction in body weight, BMI, and WC in the quercetin group, changes were negligible and did not seem to be clinically remarkable. Accordingly, resistin decrease in this group could not be due to anthropometric changes. on the relationship between resistin and glucose homeostasis (Moscavitch et al., 2016) , we expected a concurrent improvement in insulin resistance. However, some other studies found a reverse association between serum resistin and insulin sensitivity only in non-obese subject, which was disappeared after adjusting for body fat percentage (Heilbronn et al., 2004) . Probably the changes in resistin gene expression and concentration were not sufficient to improve glucose metabolism and did not properly change AMPactivated protein kinase dependent and independent mechanisms that have an important role in resistin-induced insulin resistance (Luo et al., 2009 ).
Increasing the synthesis of androgens by ovaries has been considered as a principal underlying cause of PCOS (Ehrmann, 2005) . In the present study, testosterone and LH levels decreased significantly in the quercetin compared with the placebo group following supplementation. Although some studies reported no correlation between serum resistin and testosterone in PCOS (Seow et al., 2004) , others reported that resistin could directly increase steroidogenesis by increment of luteinizing hormone receptor, steroidogenic acute regulatory protein, and the gene expression of insulin receptor. Moreover, resistin, along with LH, increases the synthesis of androgens via increase in insulin receptor gene expression (Singh, Suragani, Ehtesham, & Krishna, 2015) . Resistin could increase androgen production by stimulating ovarian theca cells and increment of Cytochrome P450 17 mRNA expression and 17α-hydroxylase activity in the presence of forskolin and forskolin plus insulin (Munir et al., 2005) . Resistin could also increase the secretion of androgens from ovaries via stimulating 3β-hydroxysteroid dehydrogenase, Cytochrome P450 11A1, Cytochrome P450 17A1, and 17β-Hydroxysteroid dehydrogenases (Rak-Mardyła, Durak, & Gregoraszczuk, 2013) . Thus, it seems that quercetin can efficiently play a role in the modulation of serum testosterone and LH, partly through reducing resistin levels.
The current study has some strengths and limitations that should be addressed. One of the strengths of this study was the assessment of the effect of a dietary antioxidant component with available food sources, and low expected adverse effects, complementary to current medications. In addition, the circulatory level and gene expression of resistin were measured simultaneously, which could strengthen the accuracy of results and reduce the role of potential covariates. One of the limitations of this trial was the lack of measurement of blood quercetin levels, which could ascertain its bioavailability. Furthermore, having a normal weight group and evaluation of body composition would allow to better interpretation of the results
and understanding the precise role of adipose tissue. Besides, since glucose levels in these patients were normal, measuring oral glucose tolerance test could be more useful.
In conclusion, 1,000 mg daily quercetin consumption in overweight or obese women with PCOS for 12 weeks, decreased resistin plasma concentration and gene expression significantly, along with considerable reduction in LH and testosterone concentration.
Following supplementation, FBG, fasting insulin, and insulin resistance were improved significantly in the quercetin group, but the changes were not statistically different compared with the placebo group.
The current findings demonstrated that quercetin might have beneficial effects in modulating some major contributors of PCOS.
The efficacy of this flavonoid compound, with especial focus on glucose homeostasis, should be further investigated as an adjuvant therapy in PCOS.
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